Physician profile
Michael G Kateman
NPI 1265923908
$17,504.21
in general payments reported to CMS, 2019-2025
30 companies · $3,869 in 2025
The $3,869 reported for 2025 was more than what 91% of Foot & Ankle Surgery providers received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,521 · 2020: $1,026 · 2021: $4,174 · 2022: $2,695 · 2023: $2,774 · 2024: $1,446 · 2025: $3,869.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,643 · Travel and Lodging: $1,447.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,642.56 |
| Travel and Lodging | $1,447.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Elite Orthopedics, LLC | $3,687.44 | 2021-2025 | |
| Arthrex, INC. | $2,902.96 | 2021-2025 | |
| Great Lakes Orthopedics | $2,367.44 | 2019-2020 | |
| Kerecis Limited | $1,693.01 | 2022-2025 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Organogenesis INC. | $1,605.34 | 2022-2025 | Puraply, Cygnus Dual, Simplimax |
| Treace Medical Concepts, INC. | $1,457.82 | 2021-2025 | |
| Stryker Corporation | $1,404.02 | 2021-2025 | Salvation, Citrefix, Hoffmann |
| Nevro Corp. | $285.30 | 2021-2024 | Senza |
| Medtronic, INC. | $245.43 | 2022-2025 | Intellis Adaptivestim, Inceptiv |
| Smith+Nephew, INC. | $224.93 | 2020-2024 | Collagenase Santyl, Grafix Pl, Regranex |
| Globus Medical, INC. | $206.09 | 2025 | Senza |
| Paratek Pharmaceuticals, INC. | $193.25 | 2021-2025 | Nuzyra |
| Bone Support INC. | $184.60 | 2019-2024 | Cerament G, Ceramentbone Void Filler |
| Bioventus LLC | $171.77 | 2025 | Exogen Ultrasound Bone Healing System |
| Tactile Systems Technology INC | $170.47 | 2025 | Flexitouch Plus, Nimbl |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $124.97 | 2019 | |
| Integra Lifesciences Corporation | $91.61 | 2021-2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Medline Industries LP | $83.17 | 2022 | |
| Zimmer Biomet Holdings, INC. | $78.76 | 2022 | |
| Paragon 28, INC. | $45.71 | 2021-2023 | Mtp |
| Trice Medical, INC. | $44.22 | 2024 | |
| Ets Wound Care LLC | $42.01 | 2024-2025 | Mirragen Advanced Wound Matrix |
| Biowound Solutions, INC. | $40.28 | 2025 | Bio-Connekt |
| Hartmann USA, INC. | $27.89 | 2021-2022 | |
| Averitas Pharma INC. | $26.38 | 2025 | Qutenza |
| Acera Surgical, INC. | $26.28 | 2022 | |
| Solventum Corporation | $23.32 | 2025 | Activ.A.C. |
| Alexion Pharmaceuticals, INC. | $16.86 | 2022 | |
| Biocomposites INC | $16.45 | 2025 | Stimulan |
| Sanara Medtech INC. | $16.43 | 2024 | Celleraterx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kateman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.